KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Accounts Payables (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Accounts Payables for 6 consecutive years, with $50.1 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Accounts Payables rose 13.93% year-over-year to $50.1 million, compared with a TTM value of $50.1 million through Jun 2025, up 13.93%, and an annual FY2024 reading of $55.0 million, up 10.94% over the prior year.
  • Accounts Payables was $50.1 million for Q2 2025 at AbCellera Biologics, up from $47.8 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $55.0 million in Q4 2024 and bottomed at $13.3 million in Q1 2021.
  • Average Accounts Payables over 5 years is $35.6 million, with a median of $32.0 million recorded in 2021.
  • The sharpest move saw Accounts Payables skyrocketed 93.55% in 2022, then decreased 5.56% in 2023.
  • Year by year, Accounts Payables stood at $32.0 million in 2021, then soared by 63.97% to $52.5 million in 2022, then decreased by 5.56% to $49.6 million in 2023, then grew by 10.94% to $55.0 million in 2024, then dropped by 8.96% to $50.1 million in 2025.
  • Business Quant data shows Accounts Payables for ABCL at $50.1 million in Q2 2025, $47.8 million in Q1 2025, and $55.0 million in Q4 2024.